Anthony Serritella
- None, NBC News
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Anthony Serritella
Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2) - Prostate Cancer and Prostatic Diseases
Abstract Unfortunately, not all metastatic castration resistant prostate cancer (mCRPC) patients receive available life-prolonging systemic therapies, emphasizing the need to optimize mCRPC treatment selections. Better guidelines are necessary to determine genetic testing in prostate cancer. In this two-part expert opinion-based guide, we provide an expert consensus opinion on the utilization of germline and somatic testing to detect HRR alterations in patients with mCRPC.
Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2) - Prostate Cancer and Prostatic Diseases
Abstract Unfortunately, not all metastatic castration-resistant prostate cancer (mCRPC) patients receive available life-prolonging systemic therapies, emphasizing the need to optimize mCRPC treatment selections. Better guidelines are necessary to determine genetic testing for prostate cancer. In this two-part expert opinion-based guide, we provide an expert consensus opinion on the utilization of germline and somatic testing to detect HRR alterations in patients with mCRPC.
Considerations in Meta-Analysis of Immunotherapy for Advanced Cancers Other Than Melanoma
Considerations in Meta-Analysis of Immunotherapy for Advanced Cancers Other Than Melanoma To the Editor Serritella and Shenoy1 conducted an interesting meta-analysis to assess the relative efficacy of nivolumab plus ipilimumab vs nivolumab for the treatment of advanced cancers other than melanoma.
The Human Soluble NKG2D Ligand Differentially Impacts Tumorigenicity and Progression in Temporal and Model-Dependent Modes
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma
Key Points Question Does combination therapy of standard-dose nivolumab and ipilimumab improve clinical outcomes and justify additional toxicity compared with nivolumab monotherapy in advanced cancers other than metastatic melanoma?
Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy
Research Article Katherine I Zhou, Bryan F Peterson, Anthony Serritella, Joseph Thomas, Natalie Reizine, Stephanie Moya, Yi-Hung Carol Tan, Yan Wang and Daniel V. T. Catenacci DOI: 10.1158/1078-0432.CCR-20-2085 Abstract Purpose: Intrapatient heterogeneity of programmed death ligand 1 (PD-L1) expression and tumor mutational burden (TMB) in gastroesophageal adenocarcinoma (GEA) could influence their roles as predictive biomarkers for response to immune checkpoint inhibitors (ICIs).
Men should ask about Prostate Cancer test, panel advises - WRCBtv.com | Chattanooga News, Weather & Sports
The controversial PSA blood test can save some men's lives from prostate cancer, an influential federal panel said in new screening guidelines. Every man between the ages of 55 and 69 is advised to talk to their doctors about taking the prostate-specific antigen blood test, according to recommendations released Tuesday by the U.S. Preventive Services Task Force.
PSA test for prostate cancer can save lives so talk to doc, panel says
The controversial PSA blood test can save some men's lives from prostate cancer, an influential federal panel said in new screening guidelines. Every man between the ages of 55 and 69 is advised to talk to their doctors about taking the prostate-specific antigen blood test, according to recommendations released Tuesday by the U.S. Preventive Services Task Force.
Celiac disease may be caused by virus, new study finds
Could a normally harmless virus cause a sensitivity to gluten? A new study has found that a certain type of virus could trigger a person’s immune system to overreact to gluten, leading to celiac disease. The findings, published Thursday in Science, provide an explanation for why certain people develop celiac disease.
New drug to treat multiple sclerosis wins FDA approval
The Food and Drug Administration approved a new drug to treat multiple sclerosis Tuesday. The drug, called Ocrevus, is approved for use against the most common form of MS - the relapsing-remitting type. It's also approved for primary progressive MS, a very aggressive form of the disease that affects 10 to 15 percent of MS patients. There are no approved treatments now for primary progressive MS, which causes steadily worsening symptoms.
Stem Cells Show Mixed Results for Impotence After Prostate Surgery
Danish researchers trying to find a way to help men badly injured by prostate cancer surgery say they got mixed results with an experimental new approach: injecting them with stem cells. Only a few of the men were helped, and those men were able to have sex after the treatment, the researchers told a meeting of urologists. The researchers' findings suggest that men should stay away — at least for now — from clinics that already offer stem cell treatment for erectile dysfunction.
Which prostate cancer treatment is best? Reports may help men decide
Once diagnosed with prostate cancer, men often face a difficult decision of choosing the best treatment. Should they have surgery, radiation or simply watch to see if the disease spreads? Two new studies give doctors and patients the clearest information yet about the possible adverse effects of these options.
Pricey new drug prevents heart attacks in high-risk patients
A new heart drug cuts cholesterol levels to once unthinkable lows, a treatment that doctors hope may prevent future heart attacks or stroke in high-risk patients, according to results from a highly anticipated study released Friday. However, the drug comes at a high price: approximately $14,000 a year. The injectable drug, Repatha, appears to cut LDL or "bad" cholesterol to extremely low levels, more than statins or lifestyle changes in people who had prior heart attacks or were at high risk.
New drug prevents heart attacks in high-risk patients - WRCBtv.com | Chattanooga News, Weather & Sports
(NBC News) - A new heart drug cuts cholesterol levels to once unthinkable lows, a treatment that doctors hope may prevent future heart attacks or stroke in high-risk patients, according to results from a highly anticipated study released Friday. However, the drug comes at a high price: approximately $14,000 a year.
'Nobody's business'? 5 things to know about the genetic testing bill
Despite the country’s focus on the American Health Care Act, a smaller bill is also working its way through Congress — one that could overturn years of legislative protections for patients. This bill would potentially pressure patients to submit to genetic testing as part of worker wellness programs, with the goal of better assessing someone’s health risk profile. If a person doesn’t agree to the tests — employers or health insurance companies could jack up their health insurance costs.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Anthony
Contact Anthony, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack